GSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe...

|By:, SA News Editor
GSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe rheumatoid arthritis. Sirukumab is among a number of drugs under development for the multi-billion dollar market for treating RA, which affects 1.5M Americans and 23.5M people globally. (PR)